Impact of 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography on Treatment Strategy and Radiotherapy Planning for Stage I-II Hodgkin Disease: A Prospective Multicenter Study
- Department of Radiation Oncology, Lyon University-Centre Leon Berard, Lyon (France)
- Department of Biostatistics, Lyon University-Centre Leon Berard, Lyon (France)
- Department of Radiation Oncology, Institut Gustave Roussy, Villejuif (France)
- Department of Radiation Oncology, APHP, Henri Mondor University Hospital, Paris 12 University, Creteil (France)
- Department of Radiation Oncology, Institut Jean Godinot, Reims (France)
- Department of Radiation Oncology, Centre Alexis Vautrin, Nancy (France)
- Department of Radiation Oncology, University Hospital Lyon Sud, Pierre Benite (France)
- Department of Radiation Oncology, University Hospital, Grenoble (France)
- Department of Radiation Oncology, Centre Antoine Lacassagne, Nice (France)
- Department of Nuclear Medicine, Lyon University-Centre Leon Berard, Lyon (France)
Purpose: To quantify the impact of preradiotherapy 18F-fluoro-2-deoxyglucose positron-emission tomography (FDG-PET) on treatment strategy and radiotherapy planning for patients with Stage I/II Hodgkin disease included in a large prospective multicenter study. Patients and Methods: Conventional computed tomography and FDG-PET were performed just before the planned radiotherapy. The radiotherapy plan was first elaborated under blinded conditions for FDG-PET data. Then, the medical staff was asked to confirm or not confirm the treatment strategy and, if appropriate, to modify the radiotherapy plan based on additional information from FDG-PET. Results: Between January 2004 and January 2006, 137 patients were included (124 were available for analysis) in 11 centers (108 adults, 16 children). All but 1 patient had received chemotherapy before inclusion. Prechemotherapy work-up included FDG-PET for 61 patients, and data were available for elaboration of the first radiotherapy plan. Based on preradiotherapy FDG-PET data, the radiotherapy was cancelled in 6 patients (4.8%), and treatment plan modifications occurred in 16 patients (12.9%): total dose (11 patients), CTV volume (5 patients), number of beam incidences (6 patients), and number of CTV (6 patients). The concordance between the treatment strategies with or without preradiotherapy FDG-PET was 82.3%. Concordance results were not significantly different when prechemotherapy PET-CT information was available. Conclusion: Preradiotherapy FDG-PET for treatment planning in Hodgkin lymphoma may lead to significant modification of the treatment strategy and the radiotherapy planning in patients with Stage I or II Hodgkin disease, even in those who have undergone FDG-PET as part of the prechemotherapy work-up.
- OSTI ID:
- 21491627
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 79, Issue 3; Other Information: DOI: 10.1016/j.ijrobp.2009.11.048; PII: S0360-3016(09)03622-0; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
[{sup 18}F]FDG-Positron Emission Tomography Coregistration With Computed Tomography Scans for Radiation Treatment Planning of Lymphoma and Hematologic Malignancies
Radiation Treatment Planning Using Positron Emission and Computed Tomography for Lung and Pharyngeal Cancers: A Multiple-Threshold Method for [{sup 18}F]Fluoro-2-Deoxyglucose Activity
Related Subjects
CHEMOTHERAPY
FLUORINE 18
FLUORODEOXYGLUCOSE
HODGKINS DISEASE
PLANNING
POSITRON COMPUTED TOMOGRAPHY
RADIOTHERAPY
ANTIMETABOLITES
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
COMPUTERIZED TOMOGRAPHY
DIAGNOSTIC TECHNIQUES
DISEASES
DRUGS
EMISSION COMPUTED TOMOGRAPHY
FLUORINE ISOTOPES
HOURS LIVING RADIOISOTOPES
IMMUNE SYSTEM DISEASES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LIGHT NUCLEI
LYMPHOMAS
MEDICINE
NANOSECONDS LIVING RADIOISOTOPES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
RADIOISOTOPES
RADIOLOGY
THERAPY
TOMOGRAPHY